Abstract
We report about a 28-year-old woman with relapsed mantle cell lymphoma (MCL, centrocytic lymphoma according to the Kiel classification) refractory to salvage chemotherapy. The patient underwent allogeneic bone marrow transplantation from a HLA-identical brother after myeloablative chemotherapy consisting of busulfan, etoposide, and cyclophosphamide. The patient experienced hepatic toxicity (grade I), mucositis (grade II) according the Bearman scale, and graft versus host disease of the skin (grade II) and showed stable engraftment with complete chimerism on day 15 after bone marrow transplantation. Eight years after transplantation, the patient is still disease free and in good condition without any late side effects. This report suggests a curative potential of allogeneic stem cell transplantation in MCL.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 23 December 1999 / Accepted: 28 March 2000
Rights and permissions
About this article
Cite this article
Kröger, N., Hoffknecht, M., Krüger, W. et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 79, 578–580 (2000). https://doi.org/10.1007/s002770000196
Issue Date:
DOI: https://doi.org/10.1007/s002770000196